182 related articles for article (PubMed ID: 35870712)
21. Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.
Kubeczko M; Gabryś D; Gawkowska M; Polakiewicz-Gilowska A; Cortez AJ; Krzywon A; Woźniak G; Latusek T; Leśniak A; Świderska K; Mianowska-Malec M; Łanoszka B; Chomik K; Gajek M; Michalik A; Nowicka E; Tarnawski R; Rutkowski T; Jarząb M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765648
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
23. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
[TBL] [Abstract][Full Text] [Related]
24. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
25. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
[TBL] [Abstract][Full Text] [Related]
26. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
[TBL] [Abstract][Full Text] [Related]
27. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
[TBL] [Abstract][Full Text] [Related]
28. [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors].
Beddok A; Porte B; Cottu P; Fourquet A; Kirova Y
Cancer Radiother; 2023 May; 27(3):240-248. PubMed ID: 37080859
[TBL] [Abstract][Full Text] [Related]
29. A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Guerini AE; Pedretti S; Salah E; Simoncini EL; Maddalo M; Pegurri L; Pedersini R; Vassalli L; Pasinetti N; Peretto G; Triggiani L; Costantino G; Figlia V; Alongi F; Magrini SM; Buglione M
Sci Rep; 2020 Aug; 10(1):13589. PubMed ID: 32788596
[TBL] [Abstract][Full Text] [Related]
30. Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors.
Yoshimoto FH; de Sousa CFPM; Marta GN; Hanna SA
Curr Oncol Rep; 2023 Oct; 25(10):1153-1159. PubMed ID: 37624551
[TBL] [Abstract][Full Text] [Related]
31. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
Chin YM; Shibayama T; Chan HT; Otaki M; Hara F; Kobayashi T; Kobayashi K; Hosonaga M; Fukada I; Inagaki L; Ono M; Ito Y; Takahashi S; Ohno S; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2022 May; 113(5):1808-1820. PubMed ID: 35201661
[TBL] [Abstract][Full Text] [Related]
32. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
34. Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil.
Queiroz MM; Sacardo KP; Ribeiro MF; Gadotti LL; Saddi R; Oliveira LJC; Linck RDM; Cruz MRS; Barroso-Sousa R; Sahade M; Correa TS; Mano MS; Suzuki DA; Shimada AK; Katz A
Cancer Treat Res Commun; 2023; 35():100683. PubMed ID: 36716534
[TBL] [Abstract][Full Text] [Related]
35. The role of CDK4/6 inhibitors in early breast cancer.
Gil-Gil M; Alba E; Gavilá J; de la Haba-Rodríguez J; Ciruelos E; Tolosa P; Candini D; Llombart-Cussac A
Breast; 2021 Aug; 58():160-169. PubMed ID: 34087775
[TBL] [Abstract][Full Text] [Related]
36. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
38. Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer.
Moukas SI; Kasimir-Bauer S; Tewes M; Kolberg HC; Hoffmann O; Kimmig R; Keup C
Sci Rep; 2023 Dec; 13(1):21262. PubMed ID: 38040730
[TBL] [Abstract][Full Text] [Related]
39. Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use.
Endo Y; Yoshimura A; Sawaki M; Hattori M; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Nozawa K; Takatsuka D; Isogai A; Iwata H
J Breast Cancer; 2022 Aug; 25(4):296-306. PubMed ID: 36031754
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real-world experience.
Peng TR; Chen JH; Wu TW
Thorac Cancer; 2023 Oct; 14(30):3012-3019. PubMed ID: 37667421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
